X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Perampanel oral suspension is first-in-class anti-epileptic agent, With epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Fycompa® (perampanel) is a highly selective, non-competitive AMPA glutamate receptor antagonist. It is indicated for the treatment of partial-onset seizures & primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Details:
Fycompa® (perampanel) is a highly selective, non-competitive AMPA glutamate receptor antagonist. It is indicated for the treatment of partial-onset seizures & primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
The completion of the acquisition, strengthens the company's Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy. Fycompa (perampanel), an oral medication, is a selective non-competitive AMPA receptor antagonist.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalyst Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $160.0 million
Deal Type: Acquisition January 25, 2023
Details:
Fycompa (perampanel) is a non-competitive AMPA glutamate receptor antagonist used to treat partial-onset seizures with or without secondarily generalized seizures, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalyst Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $160.0 million
Deal Type: Divestment December 20, 2022
Details:
Fycompa (perampanel), an oral medication, is a selective non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalyst Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $160.0 million
Deal Type: Acquisition December 19, 2022
Details:
Perampanel (Fycompa) is first-in-class AED with epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist reduces neuronal hyperexcitation.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2022
Details:
Perampanel is first-in-class anti-epileptic agent, With epileptic seizures being mediated by neurotransmitter glutamate, agent is highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2022
Details:
Fycompa is a first-in-class AED discovered at Eisai’s Tsukuba Research Laboratories. The agent is a highly selective, noncompetitive AMPA receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tsukuba Research Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
Fycompa has already been approved in China as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 12 years of age and older.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2021
Details:
The submission covering partial-onset seizures in pediatric patients was based on the results of a Phase III study of Fycompa as an adjunctive therapy conducted globally on pediatric patients with uncontrolled partial onset seizures/primary generalized tonic-clonic seizures.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
The positive opinion is to extend the use of Fycompa as an adjunctive therapy for partial-onset seizures by expanding the approved age range from 12 years & above to 4 years & above, and for primary generalized tonic-clonic seizures from 12 years & above to 7 years & above.
Lead Product(s): Perampanel
Therapeutic Area: Neurology Product Name: Fycompa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Akums Lifesciences is one of the leading API manufacturers of Cephalosporins & Oncology APIs.
